Developing Drugs and Diagnostic Tests for Integrated Cancer
                   Management,  and Treatment of Hepatitis C Virus Infection


Next Pharma Inc. (NPI) is a biotechnology company focusing on developing and commercializing products for the early detection, diagnosis, treatment and monitoring the recurrence of cancer.
Next Pharma’s novel products are  a blood test that can measure the blood level of  Aspartyl (Asparaginyl) B-Hydroxylase AABH and Drugs  ( including cLF-11 and cLF-36 that can treat HCV and different types of cancer. AABH (a novel cancer bio-marker) , cLF-11 and cLF-36 ( two novel  patented, therapeutic engineered peptides ) are the products which make  the foundation of our breakthrough technology.  Next Pharma's mission is to discover, develop and commercialize innovative therapeutic and diagnostic products for integrated cancer management as well as diseases of the liver. Our current product development focus is on novel proteins and biochemical pathways related to cellular regulation and cell cycle abnormalities in oncology, as well as hepatobiliary diseases such as Hepatitis C Virus infection.

Thank you for visiting our new Internet site. As an up-to-date business, we want to give you the opportunity to stay in touch with our company and our offers. A new content management system will enable us to always keep you up to date.